Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
I'm PortAI, I can summarize articles.
Ionis Pharmaceuticals, Inc. reported its earnings for Q3 and the first nine months of 2025. Q3 revenue increased to USD 157 million from USD 134 million year-over-year, with a net loss of USD 129 million, an improvement from USD 140 million. For the nine months, revenue rose to USD 740 million from USD 479 million, with a net loss of USD 152 million, down from USD 350 million. Basic and diluted loss per share from continuing operations improved to USD 0.8 and USD 0.95 respectively, compared to USD 0.95 and USD 2.38 a year ago.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments